Gilead Sciences (GILD) 103.84 $GILD
Market Maker Surveillance Report. EPGL, CMCSA, GILD, YHOO, MSFT, VALE, Bearishly Biased Price Friction For Wednesday, September 17th 2014
M2 - 1 hr 34 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. EP GLOBAL COMMUNICATIONS INC (OTC:EPGL), Comcast Corp (NASDAQ:CMCSA), GILEAD SCIENCES, INC. (NASDAQ:GILD), Yahoo! Inc (NASDAQ:YHOO), MICROSOFT CORPORATION (NASDAQ:MSFT), Vale SA (NYSE:VALE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Shire's Vyvanse Accepted for FDA Review for Binge Eating - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:00PM CDT
Shire plc (SHPG) recently announced that the FDA has accepted its filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse for treating adults with binge eating disorder.
UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:40PM CDT
UCB SA (UCBJF) and Amgen announced positive results from exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density.
Final Glance: Biotechnology companies
AP - Wed Sep 17, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:05PM CDT
Abbott Labs (ABT) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:45PM CDT
AstraZeneca (AZN) announced that the FDA has cleared Movantik for use in adults with chronic non-cancer pain suffering from opioid-induced constipation.
Regeneron Gets Breakthrough Therapy Status for Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:30PM CDT
Regeneron Pharmaceuticals' (REGN) shares were up 2.7% on the news that the FDA has granted Breakthrough Therapy designation to its eye drug Eylea, for the treatment of diabetic retinopathy in patients suffering from diabetic macular edema.
Rackspace and Lennar are big market movers
AP - Wed Sep 17, 3:22PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
3 Huge Stocks on Traders' Radars: SHLD, PFE, GILD
at The Street - Wed Sep 17, 1:25PM CDT
Here's how to trade some of the most active stocks on the market today.
Midday Glance: Biotechnology companies
AP - Wed Sep 17, 12:17PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Video: Gilead Stock Falls On These Drug Setbacks
at Investor's Business Daily - Wed Sep 17, 11:52AM CDT
Gilead Sciences (GILD) shares are backsliding Wednesday on news that the patient drop-out rate for hepatitis C drug Sovaldi is quadruple that of clinical trials. In addition, the biotech's Phase 2 study results that show its pancreatic cancer...
Early Glance: Biotechnology companies
AP - Wed Sep 17, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for September 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 9:10AM CDT
Benchmarks settled in the green on Tuesday following a report from Wall Street Journal stating Fed might not raise interest rate sooner-than-expected
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer
Business Wire - Wed Sep 17, 5:00AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, the addition of simtuzumab (200 mg or 700 mg) to gemcitabine did not significantly increase progression-free survival (PFS) compared to placebo plus gemcitabine. PFS was the primary endpoint of the study. Detailed results will be presented during a poster session at the European Society for Medical Oncology Congress (ESMO 2014) in Madrid, Spain, September 26-30 (Abstract #5072).
Gilead Sciences
at Investor's Business Daily - Tue Sep 16, 5:53PM CDT
Gilead Sciences (GILD) shares rose 3.7% to 104.76, as FBR analyst Andrew Berens raised his Q3 forecast for sales of blockbuster hepatitis C drug Sovaldi. Berens raised his estimate to $2.24 bil from $1.94 bil after examining Aug. prescription data...
AHF Joins National Coalition on Health Care's 'Campaign for Sustainable Rx Pricing'
Business Wire - Tue Sep 16, 5:21PM CDT
--The Bay Area drug company drew outrage--and Congressional scrutiny--by pricing its hepatitis C drug Sovaldi at $84,000 for a 12-week course of treatment--or $1,000 per pill. Pharmasset, the company that developed Sovaldi--and for which Gilead paid $11 billion cash--intended to price the drug at $36,000.
Roche Starts Trials on Lampalizumab for Geographic Atrophy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 5:10PM CDT
Roche (RHHBY) announced that it has initiated two phase III studies on ophthalmology candidate, lampalizumab.
Market Maker Surveillance Report. EPGL, CMCSA, GILD, YHOO, MSFT, VALE, Bearishly Biased Price Friction For Wednesday, September 17th 2014
M2 - 1 hr 34 mins ago
BUYINS.NET / www.buyins.net, announced today its proprietary Market Maker Friction Factor Report for Wednesday. Since October 2008 market makers are now required to be on the bid as much as they are on the offer and for like amounts of stock. This Fair Market Making Requirement is designed to prevent market makers from manipulating stock prices. On Wednesday there were 4737 companies with "abnormal" market making, 2409 companies with positive Friction Factors and 2599 companies with negative Friction Factors. Here is a list of the top companies with Abnormal Price Friction (bearish bias) in their stock prices. This means that there was more buying than selling in the stocks and their stock prices dropped. EP GLOBAL COMMUNICATIONS INC (OTC:EPGL), Comcast Corp (NASDAQ:CMCSA), GILEAD SCIENCES, INC. (NASDAQ:GILD), Yahoo! Inc (NASDAQ:YHOO), MICROSOFT CORPORATION (NASDAQ:MSFT), Vale SA (NYSE:VALE). To access Friction Factor, Naked Short Data and SqueezeTrigger Prices on all stocks please visit http://www.buyins.net .
Jim Cramer's 'Mad Money' Recap: Hooray for the Federal Reserve
at The Street - Wed Sep 17, 7:08PM CDT
Now that the Fed has done the right thing on monetary policy, investors should stop worrying and start thinking about how to make more money, Cramer says.
Merck Posts Positive Data on Osteoporosis Drug Odanacatib - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:15PM CDT
Merck & Co. Inc. (MRK) announced encouraging data from a pivotal phase III fracture outcomes study evaluating the use of odanacatib in postmenopausal women suffering from osteoporosis.
Shire's Vyvanse Accepted for FDA Review for Binge Eating - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 6:00PM CDT
Shire plc (SHPG) recently announced that the FDA has accepted its filing with priority review a supplemental New Drug Application (sNDA) for Vyvanse for treating adults with binge eating disorder.
UCB-Amgen Reveals Positive Data on Romosozumab for PMO - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 5:40PM CDT
UCB SA (UCBJF) and Amgen announced positive results from exploratory analyses of a phase II study on romosozumab in postmenopausal women with low bone mineral density.
Final Glance: Biotechnology companies
AP - Wed Sep 17, 5:04PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies were mixed at the close of trading:
Abbott Labs (ABT) to Initiate New Trial on Absorb - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 4:05PM CDT
Abbott Labs (ABT) recently announced that it will initiate a trial, ABSORB IV, on bioresorbable vascular scaffold (BVS) Absorb.
AstraZeneca's Constipation Drug Movantik Gets FDA Nod - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:45PM CDT
AstraZeneca (AZN) announced that the FDA has cleared Movantik for use in adults with chronic non-cancer pain suffering from opioid-induced constipation.
Regeneron Gets Breakthrough Therapy Status for Eylea - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 3:30PM CDT
Regeneron Pharmaceuticals' (REGN) shares were up 2.7% on the news that the FDA has granted Breakthrough Therapy designation to its eye drug Eylea, for the treatment of diabetic retinopathy in patients suffering from diabetic macular edema.
Rackspace and Lennar are big market movers
AP - Wed Sep 17, 3:22PM CDT
NEW YORK (AP) — Stocks that moved substantially or traded heavily Wednesday on the New York Stock Exchange and the Nasdaq Stock Market:
Biotech Stock Roundup: Avanir Soars on Phase II Data, Orexigen's Contrave Approved - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Sep 17, 2:00PM CDT
FDA approvals, a positive FDA panel outcome and positive phase II data were the key highlights in the biotech sector last week.
3 Huge Stocks on Traders' Radars: SHLD, PFE, GILD
at The Street - Wed Sep 17, 1:25PM CDT
Here's how to trade some of the most active stocks on the market today.
Midday Glance: Biotechnology companies
AP - Wed Sep 17, 12:17PM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 1 p.m.:
Video: Gilead Stock Falls On These Drug Setbacks
at Investor's Business Daily - Wed Sep 17, 11:52AM CDT
Gilead Sciences (GILD) shares are backsliding Wednesday on news that the patient drop-out rate for hepatitis C drug Sovaldi is quadruple that of clinical trials. In addition, the biotech's Phase 2 study results that show its pancreatic cancer...
Early Glance: Biotechnology companies
AP - Wed Sep 17, 9:29AM CDT
NEW YORK (AP) — Shares of some top biotechnology companies are mixed at 10 a.m.:
Stock Market News for September 17, 2014 - Market News
Zacks Equity Research - Zacks Investment Research - Wed Sep 17, 9:10AM CDT
Benchmarks settled in the green on Tuesday following a report from Wall Street Journal stating Fed might not raise interest rate sooner-than-expected
Gilead Announces Data From Phase 2 Study of Simtuzumab for Previously Untreated Pancreatic Cancer
Business Wire - Wed Sep 17, 5:00AM CDT
Gilead Sciences, Inc. (Nasdaq:GILD) today announced results from a Phase 2 study evaluating simtuzumab, an investigational inhibitor of lysyl oxidase-like-2 (LOXL2), in combination with gemcitabine for patients with previously untreated advanced pancreatic cancer. In the study, the addition of simtuzumab (200 mg or 700 mg) to gemcitabine did not significantly increase progression-free survival (PFS) compared to placebo plus gemcitabine. PFS was the primary endpoint of the study. Detailed results will be presented during a poster session at the European Society for Medical Oncology Congress (ESMO 2014) in Madrid, Spain, September 26-30 (Abstract #5072).
Gilead Sciences
at Investor's Business Daily - Tue Sep 16, 5:53PM CDT
Gilead Sciences (GILD) shares rose 3.7% to 104.76, as FBR analyst Andrew Berens raised his Q3 forecast for sales of blockbuster hepatitis C drug Sovaldi. Berens raised his estimate to $2.24 bil from $1.94 bil after examining Aug. prescription data...
AHF Joins National Coalition on Health Care's 'Campaign for Sustainable Rx Pricing'
Business Wire - Tue Sep 16, 5:21PM CDT
--The Bay Area drug company drew outrage--and Congressional scrutiny--by pricing its hepatitis C drug Sovaldi at $84,000 for a 12-week course of treatment--or $1,000 per pill. Pharmasset, the company that developed Sovaldi--and for which Gilead paid $11 billion cash--intended to price the drug at $36,000.
Roche Starts Trials on Lampalizumab for Geographic Atrophy - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Sep 16, 5:10PM CDT
Roche (RHHBY) announced that it has initiated two phase III studies on ophthalmology candidate, lampalizumab.
